Short-Term Exposure of Cancer Cells to Micromolar Doses of Paclitaxel, with or without Hyperthermia, Induces Long-Term Inhibition of Cell Proliferation and Cell Death In Vitro
- 307 Downloads
During intraoperative hyperthermic intraperitoneal chemotherapy for primary or secondary peritoneal malignancies, tumor cells are exposed to high drug concentrations for a relatively short period of time. We investigated in vitro the effect of paclitaxel and hyperthermia on cell proliferation, cell cycle kinetics and cell death under conditions resembling those during intraoperative hyperthermic intraperitoneal chemotherapy.
Human breast MCF-7, ovarian SKOV-3 and hepatocarcinoma HEpG2 cells were exposed to 10 and 20 μM paclitaxel at 37, 41.5 or 43°C for 2 h. Cell proliferation, cell cycle kinetics, necrosis and apoptosis were evaluated.
Hyperthermia exerted a cytostatic effect to all cell lines and at 43°C a cytotoxic effect on MCF-7 cells. MCF-7 and SKOV-3 cells treated under normothermic conditions with paclitaxel were arrested at G2/M or M phase for at least 3 days. Most of MCF-7 cells and approximately half of SKOV-3 cells were in interphase and became multinucleated without properly completing cytokinesis. Hyperthermia at 41.5°C altered cell cycle distribution and affected the paclitaxel-related effect on cell cycle kinetics of MCF-7 and SKOV-3 cells. Analysis of the mode of cell death showed that cell necrosis prevailed over apoptosis. Hyperthermia at 43°C increased paclitaxel-mediated cytotoxicity in MCF-7 cells and to a lesser extent in SKOV-3 and HEpG2 cells.
Short-time treatment of carcinoma cells with high (micromolar) concentrations of paclitaxel in normothermic and hyperthermic conditions is highly efficient for cell growth arrest and could be of clinical relevance in locoregional chemotherapy.
KeywordsPaclitaxel Intraperitoneal chemotherapy Hyperthermia Cell cycle Cell necrosis
This work was supported partly by PENED 2001, 01EΔ376 from the Greek Secretariat of Research and Technology (PAT) and the Cretan Association for Biomedical Research (PAT and SDG).
- 3.de Bree E, Rosing H, Michalakis J, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol 2006; 32:666–70Google Scholar
- 20.Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience. Semin Oncol 1997; 24(5 Suppl 15):S15–26–9Google Scholar